Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial - Concepedia

Concepedia

Publication | Open Access

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

DOI Full Paper Access

632

Citations

29

References

2019

Year

Joaquı́n Mateo, Núria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert J. Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese,

The Lancet Oncology

Abstract

Cancer Research UK, AstraZeneca, Prostate Cancer UK, the Prostate Cancer Foundation, the Experimental Cancer Medicine Centres Network, and the National Institute for Health Research Biomedical Research Centres.

References

	Year	Citations

Page 1